Health Canada OKs AAA's Lutathera agent

By staff writers

February 15, 2019 -- French molecular imaging firm Advanced Accelerator Applications (AAA) has received approval from Health Canada to market its Lutathera (lutetium-177 DOTATATE) therapeutic agent for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults with progressive disease.

NETs are rare tumors that originate in the neuroendocrine cells of numerous organs, and they are most commonly found in the lungs, gastrointestinal tract, and pancreas. Because the symptoms of NETs can mimic those of other conditions, patients with NETs are often misdiagnosed. By the time NETs are correctly diagnosed, the cancer has often metastasized to other parts of the body.

AAA is currently determining when Lutathera will be available in Canada.

Copyright © 2019

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking